ExploreWatchlistsPricing
  1. JP-listed companies
  2. Modalis Therapeutics Corporation
  3. Financials
  4. Stockholders' equity

Modalis Therapeutics Corporation (4883)

Market cap
¥4.9B
P/E ratio
Modernalis develops gene therapies for rare diseases using safe CRISPR-GNDM technology that controls genes without cutting DNA strands.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndStockholders' equity (Million JPY)YoY (%)
Dec 31, 20252,793-21.27%
Dec 31, 20243,548+157.03%
Dec 31, 20231,380-53.07%
Dec 31, 20222,941-47.00%
Dec 31, 20215,549-10.60%
Dec 31, 20206,207+61.53%
Dec 31, 20193,843+219.74%
Dec 31, 20181,202

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat